Organization
Seattle, WA
23 abstracts
Abstract
Medicaid enrollment changes among U.S. adult survivors of childhood cancer following Medicaid expansion: A report from the Childhood Cancer Survivor Study (CCSS).Org: Atlanta, GA, Seattle, WA, Toronto, ON, Canada, Memphis, TN, Salt Lake City, UT,
Abstract
Effects of immune-enhancing nutrition on radical cystectomy outcomes: Primary results from the randomized phase III double-blind clinical trial (S1600).Org: University of Kansas Medical Center, Kansas City, KS, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center, Seattle, WA,
Abstract
Analyzing correlates for cervical cancer awareness in Mauritania, Madagascar, and Benin from the Demographic Health Survey (DHS): 2017-2022.Org: Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA, Uganda Cancer Institute, Kampala, Uganda,
Abstract
ECOG-ACRIN E2197: Comparison of HER2 gene expression by RT-PCR across all HER2 immunohistochemistry groups with recurrence analysis.Org: Exact Sciences Corporation, Genomic Health Inc, Fred Hutchinson Cancer Research Center, Tisch Cancer Institute, Fox Chase Cancer Center,
Abstract
Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).Org: Winship Cancer Institute, Emory University, Atlanta, GA, USA, Cancer Research and Biostatistics, University of Kansas Medical Center, ASCO,
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
Association between financial fragility and treatment patterns in multiple myeloma.Org: Fred Hutchinson Cancer Center, Seattle, WA,
Abstract
Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).Org: Fred Hutchinson Cancer Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,
Abstract
Patient-reported fatigue and risk of treatment-related adverse events (AEs) in patients receiving systemic therapy in cancer clinical trials.Org: SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center, Seattle, WA, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Carelon Medical Benefits Management,
Abstract
Pediatric oncologist referral practices for CAR T-cell therapy: A mixed methods study.Org: Seattle Children's Hospital, University of Washington and Fred Hutchinson Cancer Research Centre, Seattle, WA, Seattle Children's Research Institute, Fred Hutchinson Cancer Center/Division of Hematology and Oncology,
Abstract
Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials.Org: Fred Hutchinson Cancer Research Center, Seattle, WA, American Society of Clinical Oncology, Alexandria, VA, Friends of Cancer Research, Washington, DC,
Abstract
A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).Org: Mayo Clinic, Rochester, MN, Phoenix, AZ, Jacksonville, FL, Clear Lake Oncology,
Abstract
Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.Org: Institut de Cancérologie Gustave Roussy, Villejuif, France, France, Perlmutter Cancer Center at NYU Langone Health Medical Center, New York, NY,
Abstract
GSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer.Org: Legorreta Cancer Center at Brown University, Providence, RI, Brown University - Lifespan Cancer Institute, NanoString Technologies, Inc., Seattle, WA,
Abstract
Association of measures of socioeconomic deprivation with healthcare utilization in elderly patients enrolled in SWOG cancer clinical trials.Org: Columbia University Medical Center, New York, NY, SWOG Statistics and Data Management Center, Seattle, WA, Seattle, WA, Fred Hutchinson Cancer Research Center,
Abstract
Association between symptoms and health-related quality of life in patients with cancer with prior or ongoing immune checkpoint inhibitor therapy exposure.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Treatment Technologies & Insights,
Abstract
B7H3 expression in sarcoma.Org: Northwestern Memorial Hospital, Chicago, IL, Chicago, IL, Northwestern University-Feinberg School of Medicine, University of Washington and Fred Hutchinson Cancer Research Centre, Seattle, WA,
Abstract
Pilot trial of the feasibility, acceptability, and potential efficacy of a pain management intervention adapted for older adults with cancer in rural settings.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Seattle, WA, Maury Regional Medical Center, Columbia,, TN, Brown University - Lifespan Cancer Institute,
Abstract
A multicenter retrospective study of the duration of adjuvant temozolomide in IDH-mutant gliomas.Org: University of Washington and Fred Hutchinson Cancer Research Centre, School of Medicine, Zhejiang University, Hangzhou, China, Seattle, WA, Stanford Medical Center, Stanford, CA,
Abstract
Social determinants of health and neurocognitive and psychosocial outcomes in adult childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).Org: Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, USA, Atlanta, GA, School of Public Health, Fudan University, University of Alberta,
Abstract
Attachment avoidance and anxiety impacting dyadic coping and communication in patients with metastatic sarcoma and their family caregivers.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Seattle, WA, Texas Tech University Health Sciences Center, El Paso, Lubbock, TX,
Abstract
Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.Org: Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, University of Pittsburgh Medical Center (UPMC), Department of Medicine, Icahn School of Medicine at Mount Sinai,